Pacific Biosciences of California, Inc. (PACB) |
|
5.27 -0.14 (-2.59%)
|
09-24 16:00 |
|
Open: |
5.31 |
Pre. Close: |
5.41 |
|
High:
|
5.585 |
Low:
|
5.1 |
|
Volume:
|
6,189,775 |
Market Cap:
|
1,185(M) |
|
|
|
|
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.59 - 5.63 |
5.63 - 5.66 |
|
Low:
|
5 - 5.05 |
5.05 - 5.09 |
|
Close:
|
5.2 - 5.27 |
5.27 - 5.32 |
|
Technical analysis |
as of: 2022-09-23 4:26:31 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.38  One year: 8.26 |
| Support: |
Support1: 5.09 Support2: 4.24 |
| Resistance: |
Resistance1: 6.32 Resistance2: 7.07 |
| Pivot: |
5.98 |
| Moving Average: |
MA(5): 5.66 MA(20): 5.94
MA(100): 5.48 MA(250): 11.95 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 16.7 %D(3): 26.6 |
| RSI: |
RSI(14): 41.5 |
| 52-week: |
High: 31.1 Low: 3.84 |
| Average Vol(K): |
3-Month: 7,830 (K) 10-Days: 6,159 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PACB ] has closed above bottom band by 13.6%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 22 Sep 2022
Plant + animal biology - Pacific Biosciences
Wed, 21 Sep 2022
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio - Nasdaq
Fri, 16 Sep 2022
Is Pacific Biosciences of California Inc (PACB) a Winner in the Medical Devices Industry? - InvestorsObserver
Wed, 14 Sep 2022
Senator Borrello Calls on Governor Hochul to Withdraw Penn Station Redevelopment Plan - The New York State Senate
Mon, 12 Sep 2022
Increasing losses over year doesn't faze investors as stock surges 26% this past week - Simply Wall St
Sat, 10 Sep 2022
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
221 (M) |
| Shares Float |
205 (M) |
|
% Held by Insiders
|
8.7 (%) |
|
% Held by Institutions
|
96.6 (%) |
|
Shares Short
|
36,030 (K) |
|
Shares Short P.Month
|
38,010 (K) |
Stock Financials |
|
EPS
|
-0.35 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.89 |
|
EPS Est Next Year
|
-0.64 |
|
Book Value (p.s.)
|
1.44 |
|
Profit Margin (%)
|
-130.2 |
|
Operating Margin (%)
|
-165.7 |
|
Return on Assets (ttm)
|
-8.8 |
|
Return on Equity (ttm)
|
-34.6 |
|
Qtrly Rev. Growth
|
14.3 |
|
Gross Profit (p.s.)
|
0.26 |
|
Sales Per Share
|
0.61 |
|
EBITDA (p.s.)
|
-0.98 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-167 (M) |
|
Levered Free Cash Flow
|
-57 (M) |
Stock Valuations |
|
PE Ratio
|
-15.5 |
|
PEG Ratio
|
3.2 |
|
Price to Book value
|
3.65 |
|
Price to Sales
|
8.63 |
|
Price to Cash Flow
|
-6.96 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
